A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

NCT01031472 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus
HIV Infections

Interventions

DRUG: GSK2248761 formulation 1
DRUG: GSK2248761 reference formulation
DRUG: GSK2248761 formulation 3
DRUG: GSK2248761 formulation 2 or 4

Sponsor

ViiV Healthcare

Collaborators

[object Object]